Sitagliptin SUN

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
27-10-2022
Toote omadused Toote omadused (SPC)
27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
17-01-2022

Toimeaine:

sitagliptin fumarate

Saadav alates:

Sun Pharmaceutical Industries Europe B.V.

ATC kood:

A10BH01

INN (Rahvusvaheline Nimetus):

sitagliptin fumarate

Terapeutiline rühm:

Drugs used in diabetes

Terapeutiline ala:

Diabetes Mellitus, Type 2

Näidustused:

For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Sitagliptin SUN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Toote kokkuvõte:

Revision: 1

Volitamisolek:

Authorised

Loa andmise kuupäev:

2021-12-09

Infovoldik

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SITAGLIPTIN SUN 25 MG FILM-COATED TABLETS
SITAGLIPTIN SUN 50 MG FILM-COATED TABLETS
SITAGLIPTIN SUN 100 MG FILM-COATED TABLETS
sitagliptin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist, or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist, or
nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Sitagliptin SUN is and what it is used for
2.
What you need to know before you take Sitagliptin SUN
3.
How to take Sitagliptin SUN
4.
Possible side effects
5.
How to store Sitagliptin SUN
6.
Contents of the pack and other information
1.
WHAT SITAGLIPTIN SUN IS AND WHAT IT IS USED FOR
Sitagliptin SUN contains the active substance sitagliptin which is a
member of a class of medicines
called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that
lowers blood sugar levels in adult
patients with type 2 diabetes mellitus.
This medicine helps to increase the levels of insulin produced after a
meal and decreases the amount of
sugar made by the body.
Your doctor has prescribed this medicine to help lower your blood
sugar, which is too high because of
your type 2 diabetes. This medicine can be used alone or in
combination with certain other medicines
(insulin, metformin, sulphonylureas, or glitazones) that lower blood
sugar, which you may already be
taking for your diabetes together with a food and exercise plan.
What is type 2 diabetes?
Type 2 diabetes is a condition in which your body does not make enough
insulin, and the insulin that
your body produces does not work as well as it should. Your body can
also make too much sugar.
When
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Sitagliptin SUN 25 mg film-coated tablets
Sitagliptin SUN 50 mg film-coated tablets
Sitagliptin SUN 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sitagliptin SUN 25 mg film-coated tablets
Each film-coated tablet contains sitagliptin fumarate, equivalent to
25 mg sitagliptin.
Excipient(s) with known effect
Each film-coated tablet contains 4 mg of hydrogenated castor oil.
Sitagliptin SUN 50 mg film-coated tablets
Each film-coated tablet contains sitagliptin fumarate, equivalent to
50 mg sitagliptin.
Excipient(s) with known effect
Each film-coated tablet contains 8 mg of hydrogenated castor oil.
Sitagliptin SUN 100 mg film-coated tablets
Each film-coated tablet contains sitagliptin fumarate, equivalent to
100 mg sitagliptin.
Excipient(s) with known effect
Each film-coated tablet contains 16 mg of hydrogenated castor oil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Sitagliptin SUN 25 mg film-coated tablets
Light pink colour, round film-coated tablets, dimensions approximately
6 mm x 3 mm, debossed with
F1 on one side and plain on the other side.
Sitagliptin SUN 50 mg film-coated tablets
Light beige colour, round film-coated tablets, dimensions
approximately 8 mm x 4 mm, debossed with
F2 on one side and plain on the other side.
Sitagliptin SUN 100 mg film-coated tablets
Beige colour, round film-coated tablets, dimensions approximately 10
mm x 4.5 mm, debossed with
F3 on one side and plain on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
3
For adult patients with type 2 diabetes mellitus, Sitagliptin SUN is
indicated to improve glycaemic
control:
as monotherapy:
•
in patients inadequately controlled by diet and exercise alone and for
whom metformin is
inappropriate due to contraindications or intolerance.
as dual oral therapy in combination with:
•
metformin when diet and exercise plus metformin alone do not provide
adequate glycaemic
control
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 27-10-2022
Toote omadused Toote omadused bulgaaria 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 17-01-2022
Infovoldik Infovoldik hispaania 27-10-2022
Toote omadused Toote omadused hispaania 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 17-01-2022
Infovoldik Infovoldik tšehhi 27-10-2022
Toote omadused Toote omadused tšehhi 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 17-01-2022
Infovoldik Infovoldik taani 27-10-2022
Toote omadused Toote omadused taani 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande taani 17-01-2022
Infovoldik Infovoldik saksa 27-10-2022
Toote omadused Toote omadused saksa 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande saksa 17-01-2022
Infovoldik Infovoldik eesti 27-10-2022
Toote omadused Toote omadused eesti 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande eesti 17-01-2022
Infovoldik Infovoldik kreeka 27-10-2022
Toote omadused Toote omadused kreeka 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 17-01-2022
Infovoldik Infovoldik prantsuse 27-10-2022
Toote omadused Toote omadused prantsuse 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 17-01-2022
Infovoldik Infovoldik itaalia 27-10-2022
Toote omadused Toote omadused itaalia 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 17-01-2022
Infovoldik Infovoldik läti 27-10-2022
Toote omadused Toote omadused läti 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande läti 17-01-2022
Infovoldik Infovoldik leedu 27-10-2022
Toote omadused Toote omadused leedu 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande leedu 17-01-2022
Infovoldik Infovoldik ungari 27-10-2022
Toote omadused Toote omadused ungari 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande ungari 17-01-2022
Infovoldik Infovoldik malta 27-10-2022
Toote omadused Toote omadused malta 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande malta 17-01-2022
Infovoldik Infovoldik hollandi 27-10-2022
Toote omadused Toote omadused hollandi 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 17-01-2022
Infovoldik Infovoldik poola 27-10-2022
Toote omadused Toote omadused poola 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande poola 17-01-2022
Infovoldik Infovoldik portugali 27-10-2022
Toote omadused Toote omadused portugali 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande portugali 17-01-2022
Infovoldik Infovoldik rumeenia 27-10-2022
Toote omadused Toote omadused rumeenia 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 17-01-2022
Infovoldik Infovoldik slovaki 27-10-2022
Toote omadused Toote omadused slovaki 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 17-01-2022
Infovoldik Infovoldik sloveeni 27-10-2022
Toote omadused Toote omadused sloveeni 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 17-01-2022
Infovoldik Infovoldik soome 27-10-2022
Toote omadused Toote omadused soome 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande soome 17-01-2022
Infovoldik Infovoldik rootsi 27-10-2022
Toote omadused Toote omadused rootsi 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 17-01-2022
Infovoldik Infovoldik norra 27-10-2022
Toote omadused Toote omadused norra 27-10-2022
Infovoldik Infovoldik islandi 27-10-2022
Toote omadused Toote omadused islandi 27-10-2022
Infovoldik Infovoldik horvaadi 27-10-2022
Toote omadused Toote omadused horvaadi 27-10-2022
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 17-01-2022

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu